Role of prolactin in the anti-diabetic effects of bromocriptine: possible action through estrogen receptor alpha in the brain
Carregando...
Data
Data de publicação
2016
Orientador
Título da Revista
ISSN da Revista
Título do Volume
É parte de
É parte de
É parte de
É parte de
PROF. ERIC A. NEWSHOLME RESEARCH SYMPOSIUM. METABOLIC REGULATION, 3rd
Exportar
Resumo
The quick release bromocriptine mesylate (Cycloset®) was recently approved as a drug to treat type 2 diabetes mellitus, but the exact mechanism of action of this drug remains unknown. Aims: We hypothesized that the anti-diabetic effects of bromocriptine is due to reductions in basal prolactin levels. Furthermore, these effects could be mediated by an interaction with estrogen receptor α (ERα) in the brain. Methodology: Initially, we studied 4 groups of obese and diabetic (ob/ob) mice for 16 days: 1) control; 2) prolactin (micro-osmotic pumps infusing prolactin; 18 μg/day); 3) bromocriptine (one daily ip injection of bromocriptine mesylate; 12 μg/g); and 4) bromocriptine + prolactin. Results: No changes in food intake were observed among the groups; however, bromocriptine groups showed a reduced weight gain along the experiment. Prolactin replacement prevented the improvement in glucose tolerance, insulin sensitivity and serum insulin levels caused by bromocriptine treatment. In another experiment, we found that ERα mRNA showed a very high co-expression with prolactin-responsive cells in hypothalamic nuclei involved in the regulation of glucose homeostasis, such as the arcuate and ventromedial nuclei. Conclusion: Our results suggest that changes in basal prolactin levels are at least partially responsible for the anti-diabetic effects of bromocriptine. These effects are possibly mediated by a crosstalk between prolactin and ERα signaling in the brain. Our findings revealed a novel mechanism that could be target of drugs to prevent and treat diabetes mellitus.
Como referenciar
FURIGO, ISADORA C.; SUZUKI, MIRIAM F.; PEDROSO, JOAO A.B.; RAMOS-LOBO, ANGELA M.; ALENCAR, AMANDA; BUONFIGLIO, DANIELLA C.; TEIXEIRA, PRYSCILA D.; ZAMPIERI, THAIS T.; OREFICE, GABRIEL; OLIVEIRA, JOAO E.; BARTOLINI, PAOLO; SOARES, CARLOS R.J.; DONATO JUNIOR, JOSE. Role of prolactin in the anti-diabetic effects of bromocriptine: possible action through estrogen receptor alpha in the brain. In: PROF. ERIC A. NEWSHOLME RESEARCH SYMPOSIUM. METABOLIC REGULATION, 3rd, 14 de julho, 2016, São Paulo, SP. Abstract... p. 84. Disponível em: http://repositorio.ipen.br/handle/123456789/27353. Acesso em: 30 Dec 2025.
Esta referência é gerada automaticamente de acordo com as normas do estilo IPEN/SP (ABNT NBR 6023) e recomenda-se uma verificação final e ajustes caso necessário.